Skip to main content Skip to footer
Algernon Pharmaceuticals Inc.
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical & Scientific Advisors
  • Alzheimer’s
    • Overview
    • AD Clinics
    • Markets
    • Resources
  • Pipeline
    • Overview
    • NP-251 (Repirinast)
    • AP-188 (DMT)
  • Companies
    • Algernon NeuroScience
  • News & Media
    • News Releases
    • IR Calendar
    • Presentations
    • Videos/Articles
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

We are currently in the process of updating our web site to reflect the announced plans to change our company name from Algernon Pharmaceuticals to Algernon Health. Please visit again soon as these changes continue to take effect across the entire web site.

News Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • News Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Annual General Meeting
    • Analysts
  • Stock Data
    • CSE:AGN
    • OTCQB:AGNPF
    • XFRA:AGW0
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • News Releases
  • IR Calendar
  • Email Alerts
Jan 07, 2021 8:00am EST

Algernon Pharmaceuticals Announces Plans for 2021

Dec 30, 2020 8:00am EST

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Dec 24, 2020 11:42am EST

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Dec 23, 2020 7:40pm EST

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

Dec 21, 2020 8:00am EST

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

Dec 17, 2020 8:00am EST

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

Dec 16, 2020 7:43pm EST

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Dec 15, 2020 8:15am EST

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

Nov 30, 2020 8:00am EST

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Nov 23, 2020 7:30am EST

Algernon Pharmaceuticals Announces 154 Patients Enrolled in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • …Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Visit us on Facebook

    Facebook

  • Visit us on Twitter

    Twitter

  • Visit us on LinkedIn

    LinkedIn

  • Email Alerts
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 Algernon Pharmaceuticals Inc. All Rights Reserved.
Privacy Policy Sitemap